# SEAMARK (NCT05217446)

> A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05217446
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Pfizer
- Conditions: Metastatic Colorectal Cancer
- Interventions: Encorafenib; Cetuximab; Pembrolizumab
- Enrollment: 108
- Primary outcome: Progression-free Survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 5
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=seamark-nct05217446